Synthesis of a Microcystis aeruginosa predicted metabolite with antimalarial activity

Peña, Stella; Scarone, Laura; Manta, Eduardo; Stewart, Lindsay B.; Yardley, Vanessa; Croft, Simon L.; Serra, Gloria

doi:10.1016/j.bmcl.2012.06.028

Cited by 29 publications

(17 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, fucoxanthin has been shown to protect DNA from photooxidation [ 237 ]. Aerucyclamide is used in pharmaceutical products as an anti-plasmodial agent isolated from the blooming of M. aeruginosa [ 238 ]. Microalgae, particularly blue-green algae, are now being considered potential sources of active ingredients that can be utilized in the treatment of cancer.…”

Section: Biological Activities Of Natural Products From Microalgaementioning

confidence: 99%

The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry for biofuels, feed, and other products

2018

View full text Add to dashboard Cite

Microalgae have recently attracted considerable interest worldwide, due to their extensive application potential in the renewable energy, biopharmaceutical, and nutraceutical industries. Microalgae are renewable, sustainable, and economical sources of biofuels, bioactive medicinal products, and food ingredients. Several microalgae species have been investigated for their potential as value-added products with remarkable pharmacological and biological qualities. As biofuels, they are a perfect substitute to liquid fossil fuels with respect to cost, renewability, and environmental concerns. Microalgae have a significant ability to convert atmospheric CO2 to useful products such as carbohydrates, lipids, and other bioactive metabolites. Although microalgae are feasible sources for bioenergy and biopharmaceuticals in general, some limitations and challenges remain, which must be overcome to upgrade the technology from pilot-phase to industrial level. The most challenging and crucial issues are enhancing microalgae growth rate and product synthesis, dewatering algae culture for biomass production, pretreating biomass, and optimizing the fermentation process in case of algal bioethanol production. The present review describes the advantages of microalgae for the production of biofuels and various bioactive compounds and discusses culturing parameters.

show abstract

Section: Biological Activities Of Natural Products From Microalgaementioning

confidence: 99%

The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry for biofuels, feed, and other products

2018

View full text Add to dashboard Cite

show abstract

“…In 2014, Peña et al reported the synthesis and antimalarial and antitrypanosomal activity of seven novel cyclohexapeptides 15 – 21 with 20 and 21 incorporating interesting thiazole functionality [ 37 ]. The study was prompted by earlier reports of cyanobacterium Microcystis aeruginosa PCC 7806 natural products, aerucyclamides A–D ( Figure 4 ), which displayed promising micromolar IC 50 (50% of maximal inhibitory concentration) values against a K1 chloroquine-resistant strain of Plasmodium falciparum [ 38 , 39 ]. The SPPS of linear hexapeptide precursors was conducted using 2-CTC resin and standard Fmoc chemistry ( Scheme 5 ).…”

Section: Solid-phase Synthesis Of Cyclohexapeptides Using Solutionmentioning

confidence: 99%

Recent Reports of Solid-Phase Cyclohexapeptide Synthesis and Applications

et al. 2018

View full text Add to dashboard Cite

Macrocyclic peptides are privileged scaffolds for drug development and constitute a significant portion of macrocyclic drugs on the market today in fields spanning from infectious disease to oncology. Developing orally bioavailable peptide-based drugs remains a challenging task; however, macrocyclization of linear peptides can be an effective strategy to improve membrane permeability, proteolytic stability, oral bioavailability, and overall drug-like characteristics for this class. Significant advances in solid-phase peptide synthesis (SPPS) have enabled the efficient construction of macrocyclic peptide and peptidomimetic libraries with macrolactamization being performed on-resin or in solution phase. The primary goal of this review is to summarize solid-phase cyclohexapeptide synthesis using the on-resin and solution-phase macrocyclization methodologies published since 2013. We also highlight their broad applications ranging from natural product total synthesis, synthetic methodology development, and medicinal chemistry, to drug development and analyses of conformational and physiochemical properties.

show abstract

“…Marine natural products play an important role in drug development particularly in anticancer, antibiotic and antiparasitic therapies. It is well known that macrocyclic peptides may demonstrate drug-like physicochemical and pharmacokinetic properties such as good metabolic stability, solubility, lipophilicity and bioavailability [ 12 ]. More than 800 secondary metabolites belonging to several classes of substances have been isolated and identified, which includes enzyme inhibitors; photosynthesis inhibitors; antimicrobial, antimitotic, immunosuppressive and antitumor peptides [ 13 - 15 ].…”

Section: Introductionmentioning

confidence: 99%

Antimycobacterial and cytotoxicity activity of microcystins

Ramos¹,

Matthiensen²,

Colvara³

et al. 2015

J Venom Anim Toxins incl Trop Dis

View full text Add to dashboard Cite

BackgroundThe present work aimed to evaluate the antimycobacterial activity and cytotoxicity of Microcystis aeruginosa toxins, the MC-LR variant and purified extract of [D-Leu1] microcystin-LR.MethodsThe antimicrobial activity of M. aeruginosa extract and microcystin was evaluated by resazurin microtiter assay against Mycobacterium tuberculosis, M. terrae, M. chelonae and M. kansasii. The cytotoxicity assay was performed by trypan blue exclusion against the HTC cell line.ResultsAntimicrobial activity was observed in the hexanic extract of M. aeruginosa (RST 9501 strain) against M. tuberculosis, including sensitive and resistant strains with minimal inhibitory concentrations (MIC) between 1.93 μM and 0.06 μM. The high activity of M. aeruginosa hexanic extract could be attributed to the major presence of the toxins MC-LR and [D-Leu1] MC-LR that showed activity at MIC between 53 and 0.42 μM against tested mycobacterial strains. Even at the highest concentration tested, no toxicity of M. aeruginosa extracts was identified against HTC cells.ConclusionsThese preliminary results suggest that [D-Leu1] MC-LR is a promising candidate for the development of a new antimycobacterial agent.

show abstract

Synthesis of a Microcystis aeruginosa predicted metabolite with antimalarial activity

Cited by 29 publications

References 30 publications

The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry for biofuels, feed, and other products

The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry for biofuels, feed, and other products

Recent Reports of Solid-Phase Cyclohexapeptide Synthesis and Applications

Antimycobacterial and cytotoxicity activity of microcystins

Contact Info

Product

Resources

About